AAIC event – Biogen and Eisai move to consolidate beta-amyloid lead

The revelation that a mid-stage trial of Biogen/Eisai’s beta-amyloid MAbBAN2401 had shown glimmers of hope has fired up the Alzheimer’s world and, along with it, the stock markets. Now comes the tricky bit: providing hard data to convince investors that BAN2401 could be clinically relevant.